AYTU · Aytu Biopharma, Inc · Metrics
Market Cap
$20.97M
Shares
10.87M
Volume · Oct 26
16.56K
Avg daily vol (3M)
34.93K
AYTU metrics
80 of 122 screener metrics currently available.
Market overview
2 metricsShare price
$1.93
Market cap
$20.97M
Price action
20 metricsPrice change (1W)
-6.9%
Price change (30D)
-12.4%
Price change (3M)
-12.0%
Price change (6M)
-24.6%
Price change (YTD)
-26.9%
Price change (1Y)
-17.4%
Trailing year
Price change (5Y)
—
52-week high
$2.90
52-week low
$1.90
Change from 52-week high
-34.5%
Change from 52-week low
+0.0%
Annualized volatility
44.4%
Annualized volatility (3M)
39.2%
Beta
0.7
RSI (14D)
36.7
Price vs SMA 50
-11.4%
Price vs SMA 200
-18.6%
Avg volume (3M)
34,832
Relative volume
0.8
Average dollar volume
$76,421
Company
3 metricsSector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Shares outstanding
10.87M
Valuation
12 metricsP / E (TTM)
—
Trailing earnings
PEG ratio
—
EV / revenue
0.1×
reciprocal yield 1,086.9%
EV / EBITDA
—
EV / EBIT
—
P / sales
0.4×
reciprocal yield 278.8%
P / book
0.6
reciprocal yield 170.8%
FCF yield
15.8%
TTM · current market cap
Buyback yield
—
P / FCF
6.3
reciprocal yield 15.8%
P / operating cash flow
6.3
reciprocal yield 15.9%
Earnings yield
-69.0%
Historical valuation
8 metricsP / E historical average (3Y)
—
P / E historical average (5Y)
—
EV / revenue historical average (3Y)
0.1×
reciprocal yield 922.0%
EV / revenue historical average (5Y)
0.2×
reciprocal yield 605.2%
EV / EBIT historical average (3Y)
—
EV / EBIT historical average (5Y)
—
EV / EBITDA historical average (3Y)
—
EV / EBITDA historical average (5Y)
—
Dividends & buybacks
7 metricsDividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
—
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—
Earnings calendar
2 metricsNext earnings
—
Last earnings
2026-09-22
Profitability
9 metricsGross margin
64.0%
Operating margin
-14.4%
Trailing 12 months
Net margin
-24.8%
Gross profit (TTM)
$36.82M
Operating profit (TTM)
−$8.31M
Net income (TTM)
−$14.25M
Trailing 12 months
Diluted EPS (TTM)
—
FCF margin
5.6%
Effective tax rate
—
Growth
11 metricsRevenue growth YoY
+6.4%
Year over year
Net income growth YoY
—
Revenue (TTM)
$57.57M
Trailing 12 months
EPS growth YoY
-352.4%
Shares change YoY
+28.1%
Year over year · more shares
Revenue CAGR (3Y)
-18.8%
Revenue CAGR (5Y)
-2.6%
EPS CAGR (3Y)
—
EPS CAGR (5Y)
—
FCF CAGR (3Y)
—
FCF CAGR (5Y)
—
Quality
14 metricsReturn on equity
-40.4%
Return on assets
-13.6%
Debt / equity
0.3
Current ratio
1.1
EBITDA (TTM)
−$4.38M
Free cash flow (TTM)
$3.25M
Quick ratio
1.0
Interest coverage
-4.4
Net debt / EBITDA
—
Return on invested capital
—
Trailing 12 months
Net cash
$15.35M
Latest balance sheet
Cash & equivalents
$26.31M
Total assets
$105.01M
Total debt
$10.96M
Cash flow & spend
7 metricsOperating cash flow (TTM)
$3.28M
Capital expenditures (TTM)
$29,000
R&D (TTM)
$0
SG&A (TTM)
$51.14M
Stock compensation (TTM)
$691,000
R&D / revenue
0.0%
Stock compensation / revenue
1.2%
Ownership (13F)
9 metrics13F filers
38
13F filer change QoQ
+1
Institutional ownership
35.3%
Conviction holders (share of 13F filers)
0.0%
Crowding (high-turnover and private-fund holders)
29.2%
Private-fund adviser ownership
29.0%
Active holders' share change QoQ
-2.2%
Holder tenure
10.0
Price vs estimated holder cost
-21.5%
Ownership (registered funds)
1 metricsIndex-fund ownership
3.1%
Short interest
3 metricsShort interest
3.0%
Latest settlement · 14.0 days to cover
Days to cover
14.0d
Short-squeeze score
64 / 100
Insider activity
2 metricsNet insider buying (90D)
—
Insider-sentiment score
—
Risk flags
1 metricsGoing concern
—